STING Agonist Antibody-Drug Conjugates for Localized Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current STING agonists used to activate immune responses against tumors often cause systemic cytokine induction, leading to off-target toxicity due to their systemic administration, which results in both on- and off-target immune responses and adverse effects.
Innovation Solution
Development of antibody-drug conjugates (ADCs) that conjugate STING agonists to antibodies via succinimide or hydrolyzed succinimide linkers attached to cysteine residues, allowing for localized immune response activation while minimizing systemic cytokine release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If STING agonists are administered systemically to activate immune response against tumors, then anti-tumor immunity is enhanced, but off-target toxicity increases due to systemic cytokine induction
Solution Approach 1:
The patent applies local quality by conjugating STING agonists to antibodies that specifically bind to tumor-associated antigens, creating a localized immune response at the tumor site. This targeted approach ensures that cytokine induction occurs primarily where the antibody-agonist complex accumulates (in tumor tissue), rather than systemically throughout the body, thereby enhancing anti-tumor immunity while minimizing off-target toxicity
Solution Approach 2:
The patent uses antibodies as intermediary carriers to deliver STING agonists specifically to tumor cells. The antibody acts as a mediator that binds both the drug (STING agonist) and the target (tumor antigen), enabling selective delivery of the immunostimulatory compound to the tumor microenvironment while avoiding systemic distribution and associated toxicities
2Reliability
If exogenous STING agonists are used to overcome immunosuppressive tumor microenvironment, then tumor regression is achieved, but pharmacokinetic properties deteriorate due to poor bioavailability and enzymatic degradation
Solution Approach 1:
The patent creates a composite molecule by chemically conjugating the STING agonist (drug component) to the antibody (carrier component) via a linker. This composite ADC structure combines the tumor-targeting capability of the antibody with the immunostimulatory activity of the STING agonist, protecting the agonist from enzymatic degradation in circulation and improving its bioavailability while maintaining its ability to induce tumor regression
Solution Approach 2:
The patent employs a stable linker to pre-protect the STING agonist from enzymatic degradation during circulation before it reaches the target. The linker maintains the integrity of the drug component during transport, ensuring that the agonist remains bioactive and available to exert its therapeutic effect once delivered to the tumor site
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ADCs provide targeted and localized induction of cytokines, reducing systemic cytokine release and associated adverse effects, thereby minimizing off-target toxicity and enhancing therapeutic efficacy in cancer treatment.
Implementation Method 1
each linker is conjugated to the antibody via a succinimide or hydrolyzed succinimide covalently linked to a sulfur atom of a cysteine residue of the antibody
Data Source
AI summary
The present disclosure provides, inter alia, antibody-drug conjugates that are useful in treating various diseases such as cancer.